Pharma: Page 2
-
Spencer Platt via Getty Images
Pfizer, looking for a jumpstart, leans into cancer drug research
Reeling from a difficult year financially, the pharma unveiled a new oncology division it says will produce eight billion-dollar medicines by 2030.
By Jonathan Gardner • March 1, 2024 -
Kevin C. Cox via Getty Images
CDC panel mulls changes to RSV vaccine recommendation
The expert committee is discussing whether, for certain older adults, to make a universal recommendation for vaccination, rather than the current policy of “shared decisionmaking.”
By Delilah Alvarado • March 1, 2024 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
A stock market run and a flurry of dealmaking have buoyed a sector that spent much of 2023 in a downturn. Can the momentum last?
By BioPharma Dive staff -
Sara Silbiger via Getty Images
Humira biosimilar from Alvotech, Teva wins FDA approval on third attempt
The companies didn’t reveal their planned price for Simlandi, which will be the 10th Humira copycat to reach the U.S. market.
By Jonathan Gardner • Feb. 26, 2024 -
Permission granted by PHC Corporation of North America
Sponsored by PHC Corporation of North AmericaChoosing laboratory equipment with workplace experience in mind
Making equipment choices with employee experience in mind can help researchers build top-performing teams while enhancing operational efficiencies.
Feb. 26, 2024 -
Peddalanka Ramesh Babu via Getty Images
J&J secures EMA backing for earlier CAR-T use in multiple myeloma
European drug regulators recommended clearing J&J and Legend Biotech's Carvykti for use as early as after first relapse, potentially giving the therapy an advantage over Bristol Myers’ Abecma.
By Ned Pagliarulo • Feb. 23, 2024 -
Win McNamee via Getty Images
Outgoing AbbVie CEO leaves a divisive Humira legacy and lasting impact on pharma
Richard Gonzalez led AbbVie to become one of the largest pharmaceutical firms, but the company's pricing and patent tactics brought criticism, too.
By Michael Gibney • Feb. 22, 2024 -
Win McNamee via Getty Images
Rick Gonzalez, longtime AbbVie CEO, to step down in July
The veteran executive, who guided AbbVie through its separation from Abbott Laboratories, will be succeeded by Chief Operating Officer Robert Michael.
By Jonathan Gardner • Feb. 20, 2024 -
Permission granted by ClinicalMind
Sponsored by ClinicalMindHere are 7 practical ways asynchronous advisory programs can make an impact in 2024
Can asynchronous advisory programs can add distinct value to your strategic mix? Yes! Here's how.
Feb. 20, 2024 -
Courtesy of Astellas Pharma
Astellas teams up with startup Kelonia to make ‘in vivo’ cell therapies
Kelonia will receive $40 million upfront through the partnership, and could receive $35 million more if Astellas opts into another program.
By Gwendolyn Wu • Feb. 16, 2024 -
Kevin Dietsch via Getty Images
Pharma CEOs, pressed by Senate panel, refuse to commit to price cuts
Forced into testifying by Senate HELP chair Bernie Sanders, the heads of Bristol Myers Squibb, J&J and Merck largely avoided major missteps.
By Jonathan Gardner • Feb. 8, 2024 -
Mario Tama via Getty Images
Obesity drug mania takes over Amgen’s earnings call
Analysts pressed company executives Tuesday on the potential of its GLP-1 drug for weight loss, early-stage results for which were published this week.
By Ned Pagliarulo • Feb. 7, 2024 -
Christopher Furlong via Getty Images
AstraZeneca to invest $300M in US cell therapy plant
The UK drugmaker is adding a facility in Rockville, Maryland, after a spate of dealmaking in the therapeutic field.
By Kristin Jensen • Feb. 7, 2024 -
JHVEPhoto via Getty Images
Obesity drugsLilly sales surge on obesity, diabetes drug demand
The company also reported trial results suggesting tirzepatide, the drug Lilly now sells as Mounjaro and Zepbound, could treat a common liver disease.
By Jonathan Gardner • Feb. 6, 2024 -
Courtesy of Johnson & Johnson
J&J says top drug prospect works across autoimmune disorders
The pharma disclosed positive results from two studies testing its antibody drug nipocalimab in generalized myasthenia gravis or Sjögren's disease.
By Jacob Bell • Feb. 5, 2024 -
Courtesy of Sanofi
Sanofi appoints Nestlé executive as new finance chief
François-Xavier Roger will replace current CFO Jean-Baptiste Chasseloup de Chatillon as Sanofi continues a research pivot and cost-cutting drive.
By Delilah Alvarado • Feb. 1, 2024 -
Marko Georgiev / Stringer via Getty Images
Merck keeps deal focus with Keytruda patent cliff on horizon
The company is open to deals the size of its prior Acceleron and Prometheus buyouts. “We continue to believe we need more,” CEO Rob Davis said.
By Ned Pagliarulo • Feb. 1, 2024 -
Courtesy of Roche
Roche shuffles early stage pipeline as it joins obesity rush
Roche said it was shelving those drugs in favor of experimental programs to treat obesity that it gained from its takeover of Carmot Therapeutics.
By Jonathan Gardner • Feb. 1, 2024 -
Warren Little via Getty Images
GSK sales of RSV vaccine stay strong, beating forecast
The British drugmaker reported Arexvy sales of about $1.5 billion for 2023, higher than the range it had previously predicted for the year.
By Delilah Alvarado • Jan. 31, 2024 -
Douglas Cliff via Getty Images
Novo resumes supplying starter doses of obesity drug Wegovy
The announcement ends a nine-month delay related to manufacturing snags that slowed Novo’s ability to meet demand for the fast-selling medicine.
By Jonathan Gardner • Jan. 31, 2024 -
Permission granted by Bristol-Myers Squibb
Bristol Myers gets positive data in subcutaneous Opdivo trial
An under-the-skin Opdivo shot produced similar results to an intravenous formulation in kidney cancer, giving Bristol Myers a chance at sustaining sales past a key patent expiration in 2028.
By Jonathan Gardner • Jan. 29, 2024 -
Mike Coppola via Getty Images
J&J focuses on newer meds to offset Stelara patent cliff
Executives talked up the company’s cash position and incremental dealmaking as ways to buttress against incoming competition.
By Michael Gibney • Jan. 24, 2024 -
Mohammed Haneefa Nizamudeen via Getty Images
Gilead ADC medicine misses goal in closely watched lung cancer study
Trodelvy didn’t outperform chemotherapy in a large study of people with a common lung tumor, a setback that sent company shares down by double digits.
By Jonathan Gardner • Jan. 22, 2024 -
Douglas Rissing via Getty Images
Sanders threatens to subpoena J&J, Merck CEOs over drug prices
The Senate HELP committee, which is seeking testimony from J&J's Joaquin Duato and Merck's Robert Davis, hasn't issued a subpoena since 1981.
By Jonathan Gardner • Jan. 19, 2024 -
Permission granted by Takeda Pharmaceuticals
Five years after Shire deal, Takeda hopes to reap rewards of latest reinvention
Amid scrutiny of Takeda’s past megamerger, Chief Scientific Officer Chris Arendt said it has built a drug pipeline that will deliver.
By Meagan Parrish • Jan. 19, 2024 -
Sean Gallup via Getty Images
Bayer signals ‘significant’ layoffs in plan to shrink bureaucracy
The company said it has secured agreement from labor representatives in Germany for job cuts that will shed “many managerial employees.”
By Kristin Jensen • Jan. 18, 2024
Previous
